1. Home
  2. EPAC vs DFTX Comparison

EPAC vs DFTX Comparison

Compare EPAC & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enerpac Tool Group Corp.

EPAC

Enerpac Tool Group Corp.

HOLD

Current Price

$37.04

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.05

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EPAC
DFTX
Founded
1910
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
EPAC
DFTX
Price
$37.04
$20.05
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$48.00
$40.25
AVG Volume (30 Days)
357.0K
1.6M
Earning Date
03-25-2026
05-04-2026
Dividend Yield
0.11%
N/A
EPS Growth
8.97
N/A
EPS
0.67
N/A
Revenue
$616,899,000.00
N/A
Revenue This Year
$5.35
N/A
Revenue Next Year
$5.51
N/A
P/E Ratio
$54.43
N/A
Revenue Growth
4.65
N/A
52 Week Low
$33.66
$14.62
52 Week High
$45.42
$19.67

Technical Indicators

Market Signals
Indicator
EPAC
DFTX
Relative Strength Index (RSI) 48.14 62.94
Support Level $34.96 $16.26
Resistance Level $38.41 N/A
Average True Range (ATR) 1.13 1.05
MACD 0.16 0.09
Stochastic Oscillator 81.26 87.99

Price Performance

Historical Comparison
EPAC
DFTX

About EPAC Enerpac Tool Group Corp.

Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: